The global prevalence of CKD has increased substantially, driven primarily by population growth and ageing.[@bib1] Declining kidney function is associated with an increased risk of CVD, with CVD being the leading cause of death in people with CKD.[@bib2] Patients with stage G3 and G4 disease, respectively, are at twofold and threefold higher risk of cardiovascular death than those with normal kidney function[@bib3] and are considered to be at high and very high cardiovascular risk.[@bib4] Furthermore, as the lipid profile worsens with declining kidney function, most patients with moderate to advanced CKD have mixed dyslipidemia and a highly atherogenic lipid profile.[@bib4] The Kidney Disease: Improving Global Outcomes Lipid Work Group[@bib5] recommends treatment with a statin or statin plus ezetimibe for adults aged ≥50 years with CKD and estimated glomerular filtration rate \<60 ml/min per 1.73 m^2^ who are not being treated with dialysis or kidney transplantation, or statin alone in those with estimated glomerular filtration rate ≥60 ml/min per 1.73 m^2^; despite this recommendation, many people with CKD are underdiagnosed and undertreated with LLT.[@bib6] Compared with end-stage kidney disease, little is known about lipid management in moderate to advanced CKD. The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study was designed to provide insights into the factors associated with progression of CKD to end-stage kidney disease or to its associated complications, and to evaluate clinical practices in patients with moderate to advanced CKD.[@bib7] The study highlighted the very high-risk profiles of patients with CKD.[@bib8] It also revealed the high prevalence of atheromatous and nonatheromatous CVD in these patients.[@bib9] Using the CKD-REIN study,[@bib7] we describe the characteristics of patients with moderate to advanced CKD according to whether they were receiving, and continued to receive at 1 year, LLT, and whether they achieved the European[@bib4] LDL-C goals for patients with high and very high cardiovascular risk.

Methods {#sec1}
=======

CKD-REIN (NCT03381950) is an ongoing prospective French cohort study that enrolled patients with CKD who attended a routine nephrology clinic between July 2013 and April 2016.[@bib7], [@bib8] The study was carried out in 40 nationally representative health facilities (public, private, nonprofit, and private for profit) that provided outpatient nephrology care. The protocol was approved by the French National Institute of Health and Medical Research (Inserm) institutional review board (IRB00003888). All patients provided informed consent to participate.

During the census phase of the study (2013−2015), we screened all patients aged ≥18 years with a proven diagnosis of moderate (stage G3) or advanced (stage G4) CKD based on 2 measures of estimated glomerular filtration rate ≥15 and \<60 ml/min per 1.73 m^2^ (done ≥1 month apart) who had not previously been on chronic dialysis or undergone kidney transplantation, and had no plans to relocate. During the inclusion phase (mid-2013 to April 2016), these eligible patients were invited to participate in the study when they attended their routine nephrology visit. Eligible patients who had moved to stage G2 or G5 (without being on dialysis or transplanted) between the census and inclusion phases were included, assuming that this would reduce selection bias resulting from variability in kidney function.

Data were extracted by trained clinical research associates from patients' medical records and hospitalization reports. Patient interviews, self-administered questionnaires, and routine biological measurements were collected at baseline and annually. The study database included information on patient characteristics (age, sex, educational level, smoking status, body mass index); medical history (CKD history, CVD history, and risk factors); laboratory measurements (CKD-Epidemiology Collaboration[@bib10]--based estimated glomerular filtration rate, LDL-C, high-density lipoprotein cholesterol, triglycerides, glucose, and glycated hemoglobin), using the value taken closest to the time of inclusion, up to 6 months before the date of inclusion; and medication use (including type of LLT) and adherence to prescribed medications. Patients were classified as having hypertension, diabetes, albuminuria, and proteinuria as defined in [Supplementary Text S1](#appsec1){ref-type="sec"}. Only treatments taken in the 3 months preceding inclusion were considered; treatments that were interrupted before this period and those started on the day of inclusion were not considered. Adherence to medication was determined using a validated score[@bib11]; this score is based on 6 questions about patient behavior, regarding their actual use of prescribed treatment; for example, whether they tend to miss medications, or to forget to take them, or whether they think they have too many medications to take. A score of 6 indicates adherence to prescribed medication; 4 to 5 indicates poor adherence; and ≤3 indicates nonadherence. Patients reported the occurrence of muscle pains and cramps using the validated Kidney Disease Quality of Life instrument and were classified as being moderately to extremely bothered versus not at all or somewhat bothered.[@bib12]

Cardiovascular history included atheromatous and nonatheromatous cardiovascular disease. Atheromatous cardiovascular disease included coronary artery disease (i.e., angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention); ischemic stroke or transient ischemic attack; and peripheral artery disease (i.e., history of amputation, angioplasty, or lower limb bypass due to atheromatous distal ischemic lesions). Nonatheromatous CVD encompassed heart failure in the absence of coronary artery disease, atrial fibrillation, other cardiac rhythm disorders, and valvular heart disease.

Low-, moderate-, and high-intensity statin treatments were defined as detailed in [Supplementary Text S2](#appsec1){ref-type="sec"}. Cardiovascular risk level was defined according to the 2016 European Society of Cardiology guidelines.[@bib4] High cardiovascular risk was defined as moderate CKD (glomerular filtration rate 30−59 ml/min per 1.73 m^2^) with no history of atheromatous CVD or diabetes; very high cardiovascular risk was defined as moderate CKD with history of atherosclerotic CVD or diabetes or severe CKD (glomerular filtration rate \<30 ml/min per 1.73 m^2^) regardless of the presence of atherosclerotic CVD or diabetes. The LDL-C goals were defined as \<2.6 mmol/l (100 mg/dl) for patients at high cardiovascular risk and \<1.8 mmol/l (70 mg/dl) for patients at very high cardiovascular risk.[@bib4]

Data on adverse drug reactions were collected prospectively over the first year of follow-up by trained clinical research associates, using patients' medical records. A pharmacologist evaluated and coded all adverse drug events, using the MedDRA international classification.

Data from patients on LLT versus not on LLT were compared using the Wilcoxon test or χ^2^ test. As patients with both CKD and type 2 diabetes have the highest cardiovascular risk, a complementary analysis in this subgroup was undertaken. LLT use by CKD stage was compared using the Cochran-Armitage trend *P* value for binary variables. LDL-C target attainment, by cardiovascular risk category, was assessed, overall and by treatment modality (no LLT, statin and/or ezetimibe, or other LLT). Among patients treated with a statin and/or ezetimibe, the odds ratios (95% confidence intervals) of reaching the LDL-C target associated with the intensity of treatment were estimated using logistic regression adjusted for age, sex, cardiovascular risk, treatment adherence, educational level, body mass index, and albuminuria. An analysis of patient characteristics at baseline according to changes in LLT over the first year of follow-up was also performed.

Results {#sec2}
=======

Between July 2013 and April 2016, 3033 patients were enrolled in the French CKD-REIN study, of whom 2542 had data on medications and LDL-C values at inclusion. After excluding 15 patients with missing treatment data at 1 year, 63 who died before starting renal replacement therapy, 81 who started renal replacement therapy, and 12 who withdrew from the study, the study population for the 1-year analysis comprised 2371 patients ([Supplementary Figure S1](#appsec1){ref-type="sec"}).

The mean (SD) age of the population was 67 (13) years, 34% were women, and 36% were obese ([Table 1](#tbl1){ref-type="table"}). More than half (53%) of the patients had a history of CVD (atherosclerotic in 37%), 90% had hypertension, and 42% had diabetes. Overall, 602 patients (24%) were classified at high cardiovascular risk, and 1886 (74%) at very high risk: 762 (30%) with CKD stage G3 and a history of atherosclerotic CVD or diabetes, and 1124 (44%) with CKD stage G4/5. The data required to determine level of cardiovascular risk were not available in 54 patients. Overall, 62% had \<12 years of education and 63% were moderately adherent or nonadherent (score \<6) with prescription medications. The mean (SD) LDL-C level was 2.7 (1.1) mmol/l; 51% had an LDL-C level \<2.6 mmol/l and 21% \<1.8 mmol/l.Table 1Baseline characteristics, overall and according to LLT at baseline**CharacteristicOverall population**[a](#tbl1fna){ref-type="table-fn"}**(*N* = 2542)On LLT**[a](#tbl1fna){ref-type="table-fn"}**(*n* = 1602)No LLT**[a](#tbl1fna){ref-type="table-fn"}**(*n* = 940)*****P*****value**[b](#tbl1fnb){ref-type="table-fn"}Age, yr, mean (SD)67 (13)68 (11)63 (15)\<0.001Women, *n* (%)875 (34)502 (31)373 (40)\<0.001BMI, kg/m^2^, mean (SD)29 (6)30 (6)27 (6)\<0.001Obese (BMI ≥30 kg/m^2^)889 (36)672 (43)217 (24)\<0.001Education \<12 yr, *n* (%)1586 (62)1064 (66)522 (56)\<0.001Adherent to medications (score of 6), *n* (%)938 (37)539 (34)399 (43)\<0.001CKD stage, *n* (%)0.1 ≤3A (≥45 ml/min per 1.73 m^2^)464 (18)270 (17)194 (21) 3B (30−44 ml/min per 1.73 m^2^)954 (38)608 (38)346 (37) 4 (15−29 ml/min per 1.73 m^2^)1025 (40)661 (41)364 (39) 5 (\<15 ml/min per 1.73 m^2^) (not on dialysis)99 (4)63 (4)36 (4)Cardiovascular risk[c](#tbl1fnc){ref-type="table-fn"}\<0.001 Normal54 (2)30 (2)24 (3) High602 (24)274 (17)328 (35) Very high1886 (74)1298 (81)588 (63)Albuminuria categories, *n* (%) (*n* = 2343)\<0.001 Normal or minimal increase (A1)651 (28)382 (26)269 (31) Moderate increase (A2)732 (31)434 (29)298 (34) Severe increase (A3)960 (41)663 (45)297 (34)Smoker (current), *n* (%)298 (12)185 (12)113 (12)0.7History of CVD, *n* (%)1335 (53)977 (61)358 (39)\<0.001Atherosclerotic CVD, *n* (%)923 (37)742 (47)181 (20)\<0.001Blood pressure \>130/80 mm Hg, *n* (%)2018 (81)1268 (81)750 (81)0.8Hypertension,[d](#tbl1fnd){ref-type="table-fn"}*n* (%)2292 (90)1503 (94)789 (84)\<0.001Diabetes, *n* (%)1071 (42)809 (51)262 (28)\<0.001Treatment for diabetes, *n* (%)895 (35)700 (44)195 (21)\<0.001Time since diagnosis of diabetes, yr, mean (SD)18 (12)18 (12)18 (12)0.1Moderately to extremely bothered by muscle pains, *n* (%)1145 (51)751 (53)394 (47)0.008Moderately to extremely bothered by cramps, *n* (%)890 (40)552 (39)338 (40)0.5Total cholesterol, mmol/l, mean (SD)4.8 (1.3)4.5 (1.2)5.4 (1.2)\<0.001LDL-C, mmol/l, mean (SD)2.7 (1.1)2.4 (1.0)3.2 (1.1)\<0.001LDL-C, mg/dl, mean (SD)104 (42)93 (38)123 (41)\<0.001LDL-C category, *n* (%) \<2.6 mmol/l (100 mg/dl)1294 (51)1032 (64)262 (28)\<0.001 \<1.8 mmol/l (70 mg/dl)543 (21)456 (28)87 (9)\<0.001HDL-C, mmol/l, mean (SD)1.3 (0.5)1.3 (0.4)1.4 (0.5)\<0.001Triglycerides, mmol/l, mean (SD)1.8 (1.0)1.9 (1.1)1.7 (1.0)\<0.001Glucose, mmol/l, mean (SD)6.3 (2.2)6.6 (2.3)5.9 (1.8)\<0.001Glycated hemoglobin, %, mean (SD)6.4 (1.2)6.6 (1.2)6.0 (1.0)\<0.001[^2][^3][^4][^5][^6]

At baseline, 63% of patients were on LLT. Compared with patients who were not on LLT, those on LLT were older, less likely to be women, and less likely to be adherent to prescription medications; but more likely to be obese, have \<12 years of education, and to have a history of CVD, diabetes, or hypertension, and to report muscle pains (all *P* \< 0.01; [Table 1](#tbl1){ref-type="table"}). In addition, they had lower LDL-C and high-density lipoprotein cholesterol levels, and higher triglyceride, glucose, and glycated hemoglobin levels (all *P* \< 0.001).

More than half (55%) of the patients were receiving monotherapy (50% with a statin) and 8% were receiving ≥2 LLTs, most frequently a statin plus ezetimibe (7%) ([Table 2](#tbl2){ref-type="table"}). Use of statin LLT increased with progressing CKD stage (*P* = 0.004). Among 1481 patients on statin and/or ezetimibe LLT and LLT intensity data, 226 (15%), 883 (60%), and 372 (25%) were on high-, moderate-, and low-intensity doses, respectively.Table 2Baseline treatment, overall and according to CKD stage**TreatmentOverall(*N* = 2542)CKD stage*P*value**[a](#tbl2fna){ref-type="table-fn"}**≤3A(*n*** **= 464)3B(*****n*** **= 954)4(*****n*** **= 1025)5(*****n*** **= 99)**LLT, *n* (%) Statin1476 (58)237 (51)564 (59)615 (60)60 (61)0.004 Fibrate77 (3)23 (5)23 (2)29 (3)2 (2)0.06 Bile acid sequestrants3 (0.1)03 (0.3)000.5 Ezetimibe231 (9)47 (10)80 (8)96 (9)8 (8)0.7 Omega 3 fatty acids30 (1)7 (2)12 (1)11 (1)00.3Classes of LLT, *n* (%) None940 (37)194 (42)346 (36)364 (36)36 (36) Monotherapy1393 (55)227 (49)537 (56)573 (56)56 (57) Statin1272 (50)196 (42)495 (52)528 (52)53 (54) Ezetimibe44 (2)9 (2)17 (2)17 (2)1 (1) Fibrate70 (3)21 (5)21 (2)26 (3)2 (2) Bile acid sequestrant2 (0.1)02 (0.2)00 Omega 3 fatty acid5 (0.2)1 (0.2)2 (0.2)2 (0.2)0 Double therapy203 (8)42 (9)68 (7)86 (8)7 (7) Statin + ezetimibe180 (7)36 (8)60 (6)77 (8)7 (7)[^7][^8]

Among patients at high cardiovascular risk, 112 of 250 (45%) of those on statin and/or ezetimibe treatment achieved the LDL-C treatment target (\<2.6 mmol/l), whereas among patients at very high cardiovascular risk, the percentage at goal (\<1.8 mmol/l) was 38% for patients with CKD stage G3 (206 of 546) and 29% for patients with CKD stage G4/5 (199 of 685) (*P* \< 0.0001; [Figure 1](#fig1){ref-type="fig"}). A minority (10%−17%) of patients who were not on any LLT or who were on LLT other than statins had LDL-C values at goal.Figure 1Achievement of low-density lipoprotein cholesterol (LDL-C) goals by cardiovascular (CV) risk level and type of treatment. \**P* values comparing the 3 risk groups. CKD, chronic kidney disease; DM, diabetes mellitus; LLT, lipid-lowering therapy. Numbers below columns indicate the population size.

Achievement of LDL-C targets increased with increasing intensity of LLT among high-risk patients, and was lower with worsening risk profiles ([Figure 2](#fig2){ref-type="fig"}). There was no significant interaction with cardiovascular risk in the relation between LLT intensity and achievement of LDL-C targets (*P*~interaction~ = 0.20). There was a trend toward higher achievement of LDL-C targets with increasing treatment intensity, before and after adjusting for potential confounders. Adjusted odds ratios for the achievement of LDL-C goals for moderate- and high- versus low-intensity LLT were 1.20 (95% confidence interval 0.92--1.56) and 1.46 (95% confidence interval 1.02--2.09), respectively (*P*~trend~ = 0.036).Figure 2Achievement of low-density lipoprotein cholesterol (LDL-C) goals according to treatment intensity (among patients on statin and/or ezetimibe) by cardiovascular (CV) risk level. \**P* values comparing the 3 treatment intensity levels within each CV risk group. CKD, chronic kidney disease; DM, diabetes mellitus; hx, history. Numbers below columns indicate the population size.

Among the subgroup of 930 patients with CKD and type 2 diabetes, LDL-C levels were significantly lower in those on LLT, and more had LDL-C levels \<2.6 or \<1.8 mmol/l compared with those not on LLT ([Supplementary Table S1](#appsec1){ref-type="sec"}).

At 1 year, 1347 patients (57%) were on the same LLT as at baseline, 801 (34%) were still not on any LLT, and 223 (9%) had modified their LLT: 78 started LLT, 98 stopped LLT, and 47 changed the type of LLT.

Compared with patients who remained on the same LLT at 1 year, patients who stopped LLT were less likely to be adherent with medications, more likely to have reported cramps at baseline, and had a worse CKD stage ([Table 3](#tbl3){ref-type="table"}). No difference was apparent in total cholesterol or LDL-C level, or in the percentage of patients with LDL-C \<1.8 mmol/l. During the first year of follow-up, no serious adverse drug reactions related to LLT were reported. Of the patients who discontinued LLT, 10% reported adverse drug reactions compared with \<1% of those who continued LLT ([Table 3](#tbl3){ref-type="table"}).Table 3Patient characteristics at baseline according to change in LLT at 1 year**CharacteristicOn LLT**[a](#tbl3fna){ref-type="table-fn"}**(*n* = 1347)Stopped LLT**[a](#tbl3fna){ref-type="table-fn"}**(*n* = 98)*****P*****value**[b](#tbl3fnb){ref-type="table-fn"}Age, yr, mean (SD)68 (11)69 (12)0.6Women, *n* (%)424 (31)27 (28)0.4BMI, kg/m^2^, mean (SD)30 (6)29 (6)0.6BMI ≥30 kg/m^2^, *n* (%)559 (42)40 (41)0.8Adherent to medications (score of 6), *n* (%)470 (35)21 (21)0.008Moderately to extremely bothered by muscle pains, *n* (%)614 (52)52 (58)0.2Moderately to extremely bothered by cramps, *n* (%)444 (37)47 (53)0.004LLT-related adverse drug events, *n* (%)4 (0.3)10 (10)\<0.001CKD stage, *n* (%)0.01 ≤3A (45−59 ml/min per 1.73 m^2^)243 (18)10 (10) 3B (30−44 ml/min per 1.73 m^2^)526 (39)37 (38) 4 (15−29 ml/min per 1.73 m^2^)548 (41)43 (44) 5 (\<15 ml/min per 1.73 m^2^) (not on dialysis)30 (2)8 (8)Total cholesterol, mmol/l, mean (SD)4.5 (1.1)4.7 (1.3)0.07LDL-C, mmol/l, mean (SD); median (range)2.4 (0.9); 2.5 (0.2--7.2)2.5 (1.2); 2.4 (0.6--5.3)0.4LDL-C category, *n* (%) \<2.6 mmol/l (100 mg/dl)879 (65)53 (54)0.03 \<1.8 mmol/l (70 mg/dl)377 (28)32 (33)0.3HDL-C, mmol/l, mean (SD)1.3 (0.4)1.3 (0.4)0.4Triglycerides, mmol/l, mean (SD)1.9 (1.0)1.8 (1.1)0.9[^9][^10][^11]

Among the patients who were receiving statin monotherapy at baseline, 10 had changed to taking more than 1 LLT and 34 to more intensive LLT treatment at 1 year. Compared with those who did not change treatment intensity, these 44 patients had similar ages, sex, body mass index, CKD stages, and high-density lipoprotein cholesterol and triglyceride levels at baseline (data not shown), but had higher total cholesterol (4.9 ± 1.3 vs. 4.4 ± 1.0 mmol/l, respectively; *P* = 0.007) and LDL-C (2.8 ± 1.0 mmol/l vs. 2.3 ± 1.0 mmol/l; *P* \< 0.001) levels. Finally, compared with their counterparts who remained untreated, patients who started LLT had similar ages, body mass index, CKD stages, and total and LDL-C levels (data not shown), but were more likely to be men (72% vs. 60%; *P* = 0.05) and to have lower high-density lipoprotein cholesterol (1.3 ± 0.5 mmol/l vs. 1.6 ± 0.5 mmol/l; *P* = 0.02) and higher triglyceride (2.0 ± 1.2 vs. 1.6 ± 0.9 mmol/l; *P* \< 0.001) levels at baseline.

Discussion {#sec3}
==========

This prospective French cohort study provides insights into the characteristics, lipid profile, and management of patients with moderate to advanced CKD who were not on dialysis or undergoing renal transplantation and were being treated by nephrologists. At inclusion in the study, 74% of patients were categorized as at very high cardiovascular risk and 24% at high cardiovascular risk. Sixty-three percent of the patients were on LLT at inclusion, most commonly statin monotherapy, with the percentage on treatment increasing with advancing CKD stage. Half of the patients had an LDL-C value that exceeded the recommended target for high-risk patients (\<2.6 mmol/l) and only 21% achieved the target for very high-risk patients (\<1.8 mmol/l).

Palmer *et al.* conducted a systematic review[@bib13] involving 50 studies (45,285 participants) that compared the benefits and harms of statins versus placebo, or no treatment, or the standard care, or another statin in adults with CKD who were not on dialysis. The authors found that statins consistently reduced the risk of death by 21% and major cardiovascular events by 28%, including in primary prevention, but they also highlighted a lack of evidence on the toxicity profile of statins in this population. These findings were consistent with a meta-analysis of 11 studies (21,295 patients with CKD, of whom 6857 were on dialysis) in which statin treatment reduced the risk of all-cause death by 34%, cardiovascular death by 31%, cardiovascular events by 45%, and stroke by 34% among patients who were not on dialysis.[@bib14] The Study of Heart And Renal Protection (SHARP) showed that lowering LDL-C with simvastatin 20 mg/d plus ezetimibe 10 mg/d versus placebo in 9270 patients with moderate to severe CKD (6247 of whom were not on dialysis) with no known history of myocardial infarction or coronary revascularization reduced the risk of major atherosclerotic events by 17% (risk ratio 0.83; 95% confidence interval 0.74--0.94).[@bib15] In light of this evidence, the Kidney Disease: Improving Global Outcomes committee recommends statin treatment in people aged ≥50 years with CKD who are not on dialysis, and combination therapy with a statin plus ezetimibe in those with stage G3 to G5 CKD.[@bib5] A German study, involving 5217 adults with moderately severe CKD under nephrological care, indicated that a substantial change in prescription practice would be necessary to meet these new recommendations.[@bib16] Consequently, it is perhaps not surprising that, despite these recommendations, a sizable percentage (37%) of the patients in the current study, all of whom were eligible for statin treatment, were not on LLT, only 9% were treated by ezetimibe, and 49% had LDL-C values that exceeded the recommended level for high-risk patients (\<2.6 mmol/l).

Patients with CKD are at higher risk than those without CKD of side effects from LLT due to reduced renal excretion, polypharmacy, and the presence of comorbid conditions. However, a quantitative meta-analysis, based on data from 23 trials (39,419 participants), found that statins reduced the rates of microalbuminuria, proteinuria, and deaths, but did not slow the clinical progression of non--end-stage CKD.[@bib17] The Kidney Disease: Improving Global Outcomes guidelines recommend the use of moderate-intensity statins (e.g., atorvastatin 20 mg, rosuvastatin 10 mg, simvastatin 40 mg, pravastatin 40 mg, fluvastatin 80 mg, or pitavastatin 2 mg) in this population,[@bib5] which may explain the low rate of use of high-intensity statins in our study. Of note, a small percentage of the patients with CKD stage G4/5 in the present study (28 patients; 3%) received fibrate treatment, which is not recommended with an estimated glomerular filtration rate \<30 ml/min per 1.73 m^2^.[@bib18]

In a subanalysis of 904 French patients with an acute coronary syndrome or with stable coronary heart disease enrolled in the DYSIS II study[@bib19] (\<5% of whom had CKD), statins were used in 97% of acute coronary syndrome patients at discharge for the index event and in 95% at 120-day follow-up, at which time 51% of the patients achieved the LDL-C goal. Among patients with stable CHD, 97% were on LLT (57% on high-intensity therapy), only 29% of whom met the LDL-C treatment target of \<1.8 mmol/l. Fewer of the patients in the current study were on LLT than in DYSIS II, and only 21% had an LDL-C value \<1.8 mmol/l.

In our study, 98 of the patients on LLT at inclusion had stopped taking it at 1 year. This change may reflect adherence issues or intolerance to LLT. Low social status, health literacy, presence of comorbid conditions, polypharmacy, negative perceptions about the treatments, high costs, and side effects can influence adherence to cardiovascular medications.[@bib20], [@bib21], [@bib22] In our study, older age, male sex, obesity, a shorter education, moderate adherence to prescription medications, history of CVD or diabetes, and hypertension medication were all more frequent among patients on LLT. Of interest, however, 65% of patients who remained on LLT achieved an LDL-C value of \<2.6 mmol/l (and 28% \<1.8 mmol/l) compared with 54% and 33%, respectively, who stopped LLT. Moreover, patients who discontinued LLT more often reported cramps at baseline and LLT-related adverse drug events over the 1-year period than their counterparts who continued LLT.

Our study has several strengths, including the representativeness of participating nephrology practice patterns and outpatients regarding the use of LLT in CKD; the large sample size of patients with detailed phenotyping; and the accuracy of the type and timing of LLT prescription. However, several limitations also must be acknowledged. Our findings are only generalizable to patients with CKD under nephrology care. We used a conservative approach to the evaluation of risk, limited to history of symptomatic CVD. However, most patients without a history of atherosclerotic CVD have imaging evidence of disease and should be categorized as at very high risk.[@bib4]

In conclusion, people with moderate to advanced CKD who are not on dialysis or undergoing renal transplantation are at substantially increased risk of CVD, and the evaluation and management of their lipid profile forms an important part of their overall care. At least half of the patients in our study had LDL-C values that exceeded the recommended target and a substantial percentage were not taking any LLT or were on monotherapy. Greater use of evidence-based LLT, including combination LLT, would be likely to increase the achievement of LDL-C treatment targets and reduce the risk of morbidity and mortality due to coronary heart disease and stroke in patients with CKD. The impact of LLT on cardiovascular outcomes will be further evaluated*.*
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**Text S1.** Classifications for hypertension, diabetes, albuminuria, and proteinuria.

**Text S2.** Low-, moderate-, and high-intensity statins.

**Table S1.** Patient baseline characteristics according to LLT in patients with type 2 diabetes.

**Figure S1.** STROBE study flow diagram.

[^1]: Members of the CKD-REIN Collaborators are listed in the [Appendix](#appsec1){ref-type="sec"}.

[^2]: BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy.

[^3]: Percentages calculated based on available data. Percentages may not add to 100 due to rounding.

[^4]: Wilcoxon test or χ^2^ test, comparing patients on LLT with those not on LLT.

[^5]: Cardiovascular risk: normal (CKD stage G2), high (CKD stage G3, no CVD or diabetes), and very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5).

[^6]: According to patient medical records or the use of antihypertensive medication.

[^7]: CKD, chronic kidney disease; LLT, lipid-lowering treatment.

[^8]: LLT use by CKD stage was compared using the Cochran-Armitage trend *P* value for binary variables.

[^9]: BMI, body mass index; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy.

[^10]: Percentages calculated based on available data.

[^11]: Wilcoxon test or χ^2^ test.
